Damora Therapeutics, Inc. (DMRA) - Total Liabilities
Based on the latest financial reports, Damora Therapeutics, Inc. (DMRA) has total liabilities worth $27.58 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Damora Therapeutics, Inc. (DMRA) defensive interval to measure how many days the company can operate on defensive assets alone.
Damora Therapeutics, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check DMRA financial resilience to evaluate the company's liquid asset resilience ratio.
Damora Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Damora Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Weaver Network Co Ltd
SHG:603039
|
China | CN¥1.62 Billion |
|
ACV Auctions Inc.
NYSE:ACVA
|
USA | $804.46 Million |
|
Westamerica Bancorporation
NASDAQ:WABC
|
USA | $5.03 Billion |
|
Laurentian Bank Of Canada
TO:LB
|
Canada | CA$47.21 Billion |
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
China | CN¥12.87 Billion |
|
Cascades Inc.
TO:CAS
|
Canada | CA$3.01 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $205.00 Million |
|
Loma Negra Compania Industrial Argentina SA ADR
NYSE:LOMA
|
USA | $874.99 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Damora Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DMRA current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Damora Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Damora Therapeutics, Inc. (2018–2025)
The table below shows the annual total liabilities of Damora Therapeutics, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.15 Million | +657.12% |
| 2024-12-31 | $2.66 Million | -54.87% |
| 2023-12-31 | $5.90 Million | -48.44% |
| 2022-12-31 | $11.44 Million | +129.07% |
| 2021-12-31 | $4.99 Million | -18.26% |
| 2020-12-31 | $6.11 Million | -24.96% |
| 2019-12-31 | $8.14 Million | +83.12% |
| 2018-12-31 | $4.44 Million | -- |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more